Abstract
Over the last years a number of reports have described elevated numbers of regulatory T (Treg) cells inside of tumors, in close proximity of the tumor, draining lymph nodes and also in peripheral blood of patients with solid tumors and hematologic malignancies. There is increasing evidence that Treg cells can migrate into tumors and suppress effective anti-tumor responses in the tumor microenvironment, thus contributing to the prosperity and growth of human tumors. In addition, several mechanisms have been described how conversion of conventional CD4+ T cells into Treg cells can occur in the context of human tumors, yet little is known about the molecular and cellular features responsible for the increase and maintenance of elevated levels of Treg cells in cancer. Recent studies now have elucidated how Treg cells mediate regulatory activity in the tumor microenvironment and enhanced our understanding of the underlying molecular mechanisms. Targeting Treg cells therefore provides an attractive therapeutic strategy to potentially influence the suppressed immune response in tumor patients thereby altering and supporting anti-tumor therapy.
Keywords: Regulatory T cells, tumor immunology, FOXP3
Current Pharmaceutical Design
Title: Regulatory T Cells: Major Players in the Tumor Microenvironment
Volume: 15 Issue: 16
Author(s): Marc Beyer and Joachim L. Schultze
Affiliation:
Keywords: Regulatory T cells, tumor immunology, FOXP3
Abstract: Over the last years a number of reports have described elevated numbers of regulatory T (Treg) cells inside of tumors, in close proximity of the tumor, draining lymph nodes and also in peripheral blood of patients with solid tumors and hematologic malignancies. There is increasing evidence that Treg cells can migrate into tumors and suppress effective anti-tumor responses in the tumor microenvironment, thus contributing to the prosperity and growth of human tumors. In addition, several mechanisms have been described how conversion of conventional CD4+ T cells into Treg cells can occur in the context of human tumors, yet little is known about the molecular and cellular features responsible for the increase and maintenance of elevated levels of Treg cells in cancer. Recent studies now have elucidated how Treg cells mediate regulatory activity in the tumor microenvironment and enhanced our understanding of the underlying molecular mechanisms. Targeting Treg cells therefore provides an attractive therapeutic strategy to potentially influence the suppressed immune response in tumor patients thereby altering and supporting anti-tumor therapy.
Export Options
About this article
Cite this article as:
Beyer Marc and Schultze L. Joachim, Regulatory T Cells: Major Players in the Tumor Microenvironment, Current Pharmaceutical Design 2009; 15 (16) . https://dx.doi.org/10.2174/138161209788453211
DOI https://dx.doi.org/10.2174/138161209788453211 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews Cardiac-Specific Expression of the Hepatocyte Growth Factor (HGF) Under the Control of a TnIc Promoter Confers a Heart Protective Effect After Myocardial Infarction (MI)
Current Gene Therapy A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism BK Polyoma Virus Nephropathy in an Immunocompromised Host
New Emirates Medical Journal The Enzymology of Cytosolic Pyrimidine 5’-Nucleotidases: Functional Analysis and Physiopathological Implications.
Current Medicinal Chemistry Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design MicroRNA Involvement in the Pathogenesis of Neuroblastoma: Potential for MicroRNA Mediated Therapeutics
Current Pharmaceutical Design Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?
Mini-Reviews in Medicinal Chemistry Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Angiogenesis in Lymphoma: A Short Review
Current Molecular Medicine One-pot Synthesis of 2,3-disubstituted-4(3<i>H</i>)-quinazolinone from o-aminobenzoic Acid and DMF Derivatives using Imidazole Hydrochloride as a Promoter
Current Organic Synthesis in vitro Anti-leukaemia Activity of Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs)
Recent Patents on Anti-Cancer Drug Discovery CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review
Protein & Peptide Letters Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation
Current Pharmaceutical Design Carcinogenicity and Chronic Rodent Toxicity of the Selective Progesterone Receptor Modulator Ulipristal Acetate
Current Drug Safety Targeting the EGFR Pathway for Cancer Therapy
Current Medicinal Chemistry Epigenetic Lesions in Malignant Melanoma
Current Pharmaceutical Biotechnology Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Current Pharmaceutical Design